Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
5.32 ^USD	-5.00%		+12.00%	-63.36%

06-24	Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from S&P Biotechnology Select Industry Index	CI
06-11	Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week	MT

Biomea Fusion, LLC announced that it has received $56 million in funding from a group of investors

January 05, 2021

On January 6, 2021, Biomea Fusion, LLC closed the transaction. The company has received $56,000,000 in a round of funding led by Cormorant Asset Management, LLC. The transaction included participation from 17 investors including Boxer Capital LLC, Janus Henderson Investors, Rock Springs Capital, Aisling Capital, a fund managed by Aisling Capital LLC, Point Sur Investors LLC, Logos Capital Management, LLC, Clifton Capital Partners, Inc, new investor, and RTW Venture Fund Limited (LSE:RTW), a fund managed by RTW Investments, LP.

Latest news about Biomea Fusion, Inc.

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from S&P Biotechnology Select Industry Index	06-23	CI
Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week	06-11	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-07	MT
Top Midday Decliners	06-07	MT
Piper Sandler Adjusts Price Target on Biomea Fusion to $10 From $45, Maintains Overweight Rating	06-07	MT
Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating	06-07	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	06-07	MT
Jobs Growth Tops Forecasts as US Equity Futures Post Narrow Losses Pre-Bell	06-07	MT
Top Premarket Decliners	06-07	MT
Barclays Downgrades Biomea Fusion to Equalweight From Overweight, Adjusts Price Target to $5 From $30	06-07	MT
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket	06-07	MT
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug	06-06	DJ
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold	06-06	MT
U.S. FDA places hold on Biomea's diabetes trial	06-06	RE
Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold	06-06	CI
Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial	05-30	MT
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes	05-30	CI
Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating	05-30	MT
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade	04-02	MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51	04-02	MT
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)	04-01	CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ

Chart Biomea Fusion, Inc.

Duration

Period

More charts

Company Profile

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Sector

Biotechnology & Medical Research

Calendar

2024-07-28 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.6 USD

Average target price

24.43 USD

Spread / Average Target

+336.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOMEA FUSION, INC.	-63.36%	201M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research